IMNM
Q4 2026 EPS Estimate
$-0.61
Nov 5, 2026
Revenue Estimate
$166,667
FY2030E EPS$1.16

Analyst Sentiment

Wall St. Consensus
Buy
13 analysts·Moderate coverage
75
Score
13 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
13100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$33.00
+19.7%
Consensus
$35.50
+28.8%
Bull
$37.00
+34.3%
12-Month Target Range13 analysts
$33.00$35.50$37.00
Current $27.56Consensus
Current Price
$27.56
Upside to Consensus
$7.94

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+10223.11%
EPS
FY2028
Rev+299.21%
EPS
FY2029
Rev+79.23%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$545,455$56M$225M$403M$613M
Low$161,426$18M$75M$119M$181M
High$913,049$111M$330M$674M$1.03B
EBITDA Avg$-109,090$-11M$-45M$-81M$-123M
Low$-182,609$-22M$-66M$-135M$-205M
High$-32,285$-4M$-15M$-24M$-36M
EBIT Avg$-109,090$-11M$-45M$-81M$-123M
Low$-182,609$-22M$-66M$-135M$-205M
High$-32,285$-4M$-15M$-24M$-36M
Net Income Avg$-188M$-189M$-106M$-7M$101M
Low$-195M$-222M$-198M$-14M$9M
High$-181M$-157M$-35M$-613,267$189M
EPS Avg$-2.14$-2.18$-1.13$-0.08$1.16
Low$-2.24$-2.55$-2.27$-0.16$0.10
High$-2.07$-1.79$-0.40$-0.01$2.17
Analysts (Rev / EPS)7 / 108 / 99 / 84 / 54 / 5
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$166,667$181,818$5M$9M$18M$26M
Low$166,667$181,818$5M$9M$18M$26M
High$166,667$181,818$5M$9M$18M$26M
EBITDA Avg$-33,333$-36,363$-942,857$-2M$-4M$-5M
Low$-33,333$-36,363$-942,857$-2M$-4M$-5M
High$-33,333$-36,363$-942,857$-2M$-4M$-5M
EBIT Avg$-33,333$-36,363$-942,857$-2M$-4M$-5M
Low$-33,333$-36,363$-942,857$-2M$-4M$-5M
High$-33,333$-36,363$-942,857$-2M$-4M$-5M
Net Income Avg$-63M$-67M$-67M$-61M$-58M$-64M
Low$-67M$-82M$-67M$-61M$-58M$-64M
High$-61M$-41M$-67M$-61M$-58M$-64M
EPS Avg$-0.56$-0.59$-0.59$-0.54$-0.51$-0.57
Low$-0.59$-0.72$-0.59$-0.54$-0.51$-0.57
High$-0.54$-0.36$-0.59$-0.54$-0.51$-0.57
Analysts (Rev / EPS)6 / 99 / 137 / 54 / 54 / 57 / 5

Earnings Surprises

Recent Analyst Actions

Aug 12, 2026Wedbush
Immunome price target raised to $35 from $31 at Wedbush
Target:$35.00
+33.2%from $26.27
May 28, 2026Truist Financial
Immunome Inc. (IMNM) PT Raised to $37 at Truist Securities, Assumes Coverage
Target:$37.00
+67.3%from $22.11
May 28, 2026Barclays
Barclays Starts Immunome Inc. (IMNM) at Overweight
Target:$36.00
+62.8%from $22.11
May 15, 2026Leerink Partners
Immunome price target lowered to $33 from $37 at Leerink
Target:$33.00
+49.9%from $22.02
Feb 12, 2026H.C. Wainwright
Immunome initiated with a Buy at H.C. Wainwright
Target:$40.00
+70.9%from $23.41
Dec 16, 2025Lake Street
Immunome price target raised to $32 from $22 at Lake Street
Target:$32.00
+36.8%from $23.39
Dec 16, 2025Evercore ISI
Immunome price target raised to $40 from $18 at Evercore ISI
Target:$40.00
+71.3%from $23.35
Dec 15, 2025Leerink Partners
Immunome price target raised to $40 from $38 at Leerink
Target:$40.00
+76.6%from $22.65
Dec 1, 2025Truist Financial
Immunome initiated with a Buy at Truist
Target:$36.00
+95.4%from $18.42
Nov 17, 2025Stephens
Immunome Inc. (IMNM) PT Raised to $33 at StephensMember Login
Target:$33.00
+92.5%from $17.14
Sep 5, 2025Craig-Hallum
Immunome initiated with a Buy at Craig-Hallum
Target:$26.00
+147.1%from $10.52
Aug 22, 2025Evercore ISI
Immunome initiated with an Outperform at Evercore ISI
Target:$18.00
+74.8%from $10.30
Aug 13, 2024Piper Sandler
Immunome price target lowered to $23 from $27 at Piper Sandler
Target:$23.00
+82.0%from $12.64
Apr 15, 2024Guggenheim
Immunome initiated with a Buy at Guggenheim
Target:$35.00
+70.1%from $20.58
Apr 1, 2024Wedbush
Immunome price target raised to $33 from $27 at Wedbush
Target:$33.00
+33.7%from $24.68
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.